文献速递眼底病与葡萄膜炎眼整形与眼眶

葡萄膜黑色素瘤二次治疗后的重复基因表达谱、PRAME状态及二代测序结果

Repeat Gene Expression Profiling, Preferentially Expressed Antigen in Melanoma Status, and Next-Generation Sequencing Testing in Uveal Melanoma Undergoing Secondary Therapy.
PubMed 文献 · Am J Ophthalmol · 2026-08-25

回顾性分析49例初诊接受斑块放疗后需眼球摘除或二次斑块近距离放疗的脉络膜黑色素瘤患者,比较初次与二次手术的基因表达谱(GEP)分类、PRAME状态及二代测序(NGS)结果。结果显示GEP分类一致率为83.6%(41/49),PRAME状态一致率为87.1%(27/31),NGS结果在17例中均不变;

要点

  • 斑块放疗后GEP分类和PRAME状态在多数患者中保持稳定,一致率分别为83.6%和87.1%。
  • 因新生血管性青光眼行眼球摘除的15眼中,GEP分类和PRAME状态均无变化。

核心结论

  • 斑块放疗后GEP分类和PRAME状态在约84%和87%的患者中仍是可靠标志物。
  • 肿瘤复发或对斑块治疗抵抗时这些生物标志物可能改变,提示肿瘤微环境随进展发生变化。

研究设计与样本

  • 回顾性病例系列,纳入49例初诊斑块放疗后需眼球摘除(41例)或二次斑块近距离放疗(8例)的脉络膜黑色素瘤患者。
  • 每次手术行细针穿刺活检,分别用DiagnosticDx-UM、DiagnosticDx-PRAME和DiagnosticDx-UMSeq(Castle Biosciences)检测GEP分类、PRAME状态和NGS结果。

主要发现

  • 因新生血管性青光眼摘除的15眼中,GEP分类和PRAME状态均无变化。
  • 17例初次和二次手术均有NGS结果者,NGS发现均不变。

临床怎么用

  • 斑块放疗后重复活检GEP和PRAME多数稳定,可辅助判断肿瘤生物学行为。
  • 对放疗后肿瘤厚度较大或怀疑复发/抵抗者,重复检测可能发现标志物改变。
  • 新生血管性青光眼需眼球摘除者,GEP和PRAME多无变化,提示该并发症未必伴随肿瘤生物学改变。

局限性

  • 回顾性病例系列,样本量有限(49例,部分检测配对结果更少)。
  • 仅纳入需二次手术(眼球摘除或二次斑块放疗)的患者,存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare first and repeat gene expression profiling (GEP) class, preferentially expressed antigen in melanoma (PRAME) status, and next-generation sequencing (NGS) results in choroidal melanoma patients who required either enucleation or secondary plaque brachytherapy following initial plaque radiotherapy. DESIGN: Retrospective case series. METHODS: In this study, 49 patients were included, 41 underwent enucleation, and 8 underwent secondary plaque brachytherapy after initial plaque radiotherapy. Fine needle aspiration biopsy was performed at each procedure to determine GEP class and PRAME status, as well as to obtain the NGS results, using DiagnosticDx-UM, DiagnosticDx-PRAME, and DiagnosticDx-UMSeq, respectively (Castle Biosciences). RESULTS: GEP classification remained concordant between initial and secondary procedures in 41 of 49 patients (83.6%; P = .07). Among 31 patients with paired PRAME test results, 27 (87.1%) demonstrated concordance (P = .625). Notably, no changes in GEP class or PRAME status were observed among the 15 eyes enucleated for neovascular glaucoma. NGS findings remained unchanged in all 17 patients with results available from both the initial and secondary surgeries. Mean tumor thickness following the initial plaque radiotherapy was significantly greater in patients who exhibited a change in GEP class compared with those who did not (P = .027). Additionally, GEP discriminant scores decreased significantly after initial plaque radiotherapy (P < .05). CONCLUSIONS: The GEP class and PRAME status remain reliable markers for choroidal melanoma following plaque radiotherapy in 84% and 87% of patients, respectively. However, changes in these biomarkers may be observed in cases of tumor recurrence or resistance to plaque therapy, suggesting alterations in the tumor microenvironment as related to tumor progression.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Arslan GD, Alizada M, Ciftci S, et al. Repeat Gene Expression Profiling, Preferentially Expressed Antigen in Melanoma Status, and Next-Generation Sequencing Testing in Uveal Melanoma Undergoing Secondary Therapy. Am J Ophthalmol. 2026. PMID: 42641904. doi:10.1016/j.ajo.2026.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。